PRESTIGE CONSUMER HEALTHCARE INC. (PBH) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 153.81M USD | Liabilities, Current |
| Cash and equivalents | 89.13M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 187.35M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 190.22M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $153.81M | $89.13M | (m) | $187.35M | $190.22M | (m) |
| 2026-03-31 | (m) | $120.92M | $63.87M | (m) | $191.92M | $159.13M | (m) |
| 2025-12-31 | (m) | $139.56M | $62.37M | (m) | $190.46M | $163.59M | (m) |
| 2025-09-30 | (m) | $134.60M | $119.11M | (m) | $199.00M | $159.00M | (m) |
| 2025-06-30 | (m) | $109.67M | $139.50M | (m) | $168.41M | $153.13M | (m) |
| 2025-03-31 | (m) | $106.62M | $97.88M | (m) | $194.29M | $147.71M | (m) |
| 2024-12-31 | (m) | $102.55M | $50.87M | (m) | $167.27M | $151.52M | (m) |
| 2024-09-30 | (m) | $106.91M | $51.54M | (m) | $163.55M | $156.22M | (m) |
| 2024-06-30 | (m) | $114.11M | $34.26M | (m) | $171.69M | $152.04M | (m) |
| 2024-03-31 | (m) | $117.05M | $46.47M | (m) | $176.78M | $138.72M | (m) |
| 2023-12-31 | (m) | $127.44M | $63.62M | (m) | $174.29M | $148.64M | (m) |
| 2023-09-30 | (m) | $129.70M | $60.07M | (m) | $158.46M | $161.28M | (m) |
| 2023-06-30 | (m) | $147.27M | $54.58M | (m) | $157.95M | $169.85M | (m) |
| 2023-03-31 | (m) | $160.72M | $58.49M | (m) | $167.02M | $162.12M | (m) |
| 2022-12-31 | (m) | $160.18M | $86.36M | (m) | $157.08M | $158.52M | (m) |
| 2022-09-30 | (m) | $152.31M | $42.44M | (m) | $145.99M | $140.50M | (m) |
| 2022-06-30 | (m) | $155.35M | $35.87M | (m) | $145.45M | $133.77M | (m) |
| 2022-03-31 | (m) | $143.42M | $27.18M | (m) | $139.33M | $120.34M | (m) |
| 2021-12-31 | (m) | $135.13M | $21.02M | (m) | $134.26M | $106.27M | (m) |
| 2021-09-30 | (m) | $148.94M | $42.82M | (m) | $146.55M | $107.92M | (m) |
| 2021-06-30 | (m) | $125.05M | $163.62M | (m) | $130.35M | $105.55M | (m) |
| 2021-03-31 | (m) | $122.14M | $32.30M | (m) | $114.67M | $114.96M | (m) |
| 2020-12-31 | (m) | $126.16M | $62.10M | (m) | $116.00M | $117.01M | (m) |
| 2020-09-30 | (m) | $136.12M | $26.60M | (m) | $122.21M | $114.03M | (m) |
| 2020-06-30 | (m) | $131.93M | $57.94M | (m) | $112.32M | $116.81M | (m) |
| 2020-03-31 | (m) | $149.88M | $94.76M | (m) | $150.52M | $116.03M | (m) |
| 2019-12-31 | (m) | $149.04M | $28.59M | (m) | $144.50M | $121.36M | (m) |
| 2019-09-30 | (m) | $146.89M | $27.91M | (m) | $142.60M | $126.36M | (m) |
| 2019-06-30 | (m) | $143.49M | $29.04M | (m) | $142.93M | $129.39M | (m) |
| 2019-03-31 | (m) | $126.98M | $27.53M | (m) | $148.79M | $119.88M | (m) |
| 2018-12-31 | (m) | $128.82M | $24.67M | (m) | $140.58M | $120.37M | (m) |
| 2018-09-30 | (m) | $145.97M | $36.91M | (m) | $153.85M | $113.57M | (m) |
| 2018-06-30 | (m) | $142.26M | $34.27M | (m) | $150.39M | $118.96M | (m) |
| 2018-04-01 | (m) | (m) | (m) | (m) | $146.32M | $116.78M | (m) |
| 2018-03-31 | (m) | $123.20M | $32.55M | (m) | $140.88M | $118.55M | (m) |
| 2017-12-31 | (m) | $151.50M | $45.38M | (m) | $150.42M | $114.89M | (m) |
| 2017-09-30 | (m) | $160.72M | $42.98M | (m) | $145.42M | $119.48M | (m) |
| 2017-06-30 | (m) | $153.62M | $44.13M | (m) | $134.72M | $118.71M | (m) |
| 2017-03-31 | (m) | $162.01M | $41.85M | (m) | $136.74M | $115.61M | (m) |
| 2016-12-31 | (m) | $132.32M | $63.29M | (m) | $104.39M | $100.93M | (m) |
| 2016-09-30 | (m) | $114.31M | $30.46M | (m) | $92.87M | $97.96M | (m) |
| 2016-06-30 | (m) | $100.14M | $28.88M | (m) | $88.44M | $92.87M | (m) |
| 2016-03-31 | (m) | $106.68M | $27.23M | (m) | $95.25M | $91.26M | (m) |
| 2015-12-31 | (m) | $86.72M | $48.97M | (m) | $85.08M | $80.67M | (m) |
| 2015-09-30 | (m) | $93.03M | $22.15M | (m) | $91.34M | $77.14M | (m) |
| 2015-06-30 | (m) | $101.79M | $21.60M | (m) | $85.58M | $74.08M | (m) |
| 2015-03-31 | (m) | $99.04M | $21.32M | (m) | $87.86M | $74.00M | (m) |
| 2014-12-31 | (m) | $91.03M | $21.95M | (m) | $87.69M | $75.24M | (m) |
| 2014-09-30 | (m) | $111.91M | $21.75M | (m) | $98.64M | $82.88M | (m) |
| 2014-06-30 | (m) | $78.32M | $15.68M | (m) | $58.24M | $66.17M | (m) |
| 2014-03-31 | (m) | $84.36M | $28.33M | (m) | $65.05M | $65.59M | (m) |
| 2013-12-31 | (m) | $134.06M | $94.35M | (m) | $66.19M | $64.80M | (m) |
| 2013-09-30 | (m) | $89.11M | $26.83M | (m) | $80.53M | $61.94M | (m) |
| 2013-06-30 | (m) | $81.73M | $19.31M | (m) | $61.98M | $66.92M | (m) |
| 2013-03-31 | (m) | $96.67M | $15.67M | (m) | $73.05M | $60.20M | (m) |
| 2012-12-31 | (m) | $88.75M | $10.43M | (m) | $73.75M | $54.25M | (m) |
| 2012-09-30 | (m) | $88.40M | $29.01M | (m) | $84.77M | $53.84M | (m) |
| 2012-06-30 | (m) | $63.19M | $4.40M | (m) | $69.42M | $53.85M | (m) |
| 2012-03-31 | (m) | $63.92M | $19.02M | (m) | $60.23M | $51.11M | (m) |
| 2011-12-31 | (m) | $53.06M | $4.44M | (m) | $50.16M | $43.58M | (m) |
| 2011-09-30 | (m) | $56.13M | $7.96M | (m) | $49.45M | $46.41M | (m) |
| 2011-06-30 | (m) | $49.81M | $5.99M | (m) | $43.80M | $43.72M | (m) |
| 2011-03-31 | (m) | $54.21M | $13.33M | (m) | $44.39M | $39.75M | (m) |
| 2010-12-31 | (m) | (m) | $83.27M | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $55.03M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $33.11M | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | $41.10M | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | $35.18M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |